Literature DB >> 9447610

Segmental distribution of muscle weakness in SMA III: implications for deterioration in muscle strength with time.

F Deymeer1, P Serdaroğlu, M Poda, Y Gülşen-Parman, T Ozçelik, C Ozdemir.   

Abstract

We examined 26 spinal muscular atrophy type III (SMA III) patients with SMNt deletions, searching for possible segmental distribution of muscle weakness. In those with disease duration of < or = 11 years, the weakest muscles were upper lumbar innervated ones in the lower extremities. In the upper extremities, early involvement of triceps muscle suggested the possibility of lower cervical (C7) onset. Electrophysiologically, weaker muscles had a more severe reduction in the recruitment pattern, particularly in the lower extremities. However, severe reduction in recruitment was sometimes also observed in clinically strong muscles. In patients with disease duration of > or = 16 years and regardless of disease duration, in those with disease onset at < or = 3 years of age, weakness and severe electrophysiological changes were more widespread. These findings may suggest a progression in muscle weakness with time. When compared to 12 patients with Becker muscular dystrophy (BMD), early stage SMA III with weak iliopsoas-strong gluteus maximus stood in contrast to BMD with weak gluteus maximus-strong iliopsoas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447610     DOI: 10.1016/s0960-8966(97)00113-2

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

1.  Segmental Spinal Muscular Atrophy Localised to the Lower Limbs: First case from Oman.

Authors:  Roshan Koul; Amna Al-Futaisi; Khalid Al-Thihli; Zandre Bruwer; Patrick Scott
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

2.  Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative?

Authors:  Jacqueline Montes; Carol Ewing Garber; Samantha S Kramer; Megan J Montgomery; Sally Dunaway; Shirit Kamil-Rosenberg; Brendan Carr; Rosangel Cruz; Nancy E Strauss; Douglas Sproule; Darryl C De Vivo
Journal:  J Neuromuscul Dis       Date:  2015-10-07

3.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

4.  Neuroanatomical Models of Muscle Strength and Relationship to Ambulatory Function in Spinal Muscular Atrophy.

Authors:  Rafael Rodriguez-Torres; Julia Fabiano; Ashley Goodwin; Ashwini K Rao; Stacy Kinirons; Darryl De Vivo; Jacqueline Montes
Journal:  J Neuromuscul Dis       Date:  2020

5.  Multi-parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy.

Authors:  Melissa T Hooijmans; Laura E Habets; Sandra A M van den Berg-Faay; Martijn Froeling; Fay-Lynn Asselman; Gustav J Strijkers; Jeroen A L Jeneson; Bart Bartels; Aart J Nederveen; W Ludo van der Pol
Journal:  NMR Biomed       Date:  2022-02-14       Impact factor: 4.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.